NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Aspect Biosystems

Aspect Biosystems

Private
VancouverHealthcare & Life Scienceshttps://aspectbiosystems.com/

Last Round

Grant

Apr 2, 2026

Total Funding Raised

$249.28M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Aspect Biosystems is a biotechnology company that develops a full-stack tissue therapeutic platform using proprietary AI-powered bioprinting technology to create implantable bioprinted tissue therapeutics for metabolic and endocrine diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, 3D Printing, Biotech Equipment, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Hardware Sales

AI Layer

Application

Keywords

3D bioprintingtissue engineeringbioprinted therapeuticsdrug discoveryregenerative medicinebioprinting platformorgan-on-a-chipcomputational tissue designcontract research servicesbiotech equipmentbiomanufacturingtissue modelinglab-grown tissuebiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Aspect Biosystems Comps

Public and private peers based on sector, stage, and business model.

Aspect Biosystems comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Aspect Biosystems Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantApr 2, 2026
Series BJan 8, 2025
GrantJul 10, 2024
GrantMar 20, 2023
Series AJan 9, 2020
Grant
Nov 15, 2018

Key People

Founding team and executive leadership

Tamer Mohamed

Founder & CEO

Founding Team

Simon Beyer

Chief Technology Officer

Executive Team

Ray Smith

Chief Financial Officer

Executive Team

Aspect Biosystems Investors

Notable investors and investment history

Aspect Biosystems investors
InvestorRounds
InBC Investment Corp.Series B
Genome British ColumbiaVC Round
DimensionSeries B
Government of British ColumbiaGrant
Government of CanadaGrant
JDRFSeries B
Endure CapitalVC Round, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 2, 2026

    $57M grant funding secured.

  • Jan 23, 2026

    Will develop therapies based on stem cell-derived islets.

Aspect Biosystems Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Aspect Biosystems Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Aspect Biosystems's valuation, stock price, and market status.

Firmographic Details

HeadquartersVancouver
Employee Range143
Year Founded2013
Last FundingApr 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.